from the March 2008 issue

Rafael offers Jamming technology for slower aircraft

Rafael is offering its Jam-Air directional infra-red countermeasures anti-missile system for use on small, slow aircraft. The Jam-Air was originally developed to protect helicopters but according to lova Drori, Rafael's vice-president of marketing, the system can be installed on small aircraft that fly relatively slowly.

The Israeli air force has begun equipping its helicopters with the Jam-Air.The system is replacing the AN/ALQ-144, an omni-directional active infra-red countermeasures system, which according to the the IAF is no longer sufficient for current threats.

The Jam-Air is housed in a gimballed turret and based on an arc lamp technology that produces a wide beam that jams the IR seeker of the missile by disengaging the sensor's lock on the heat source..

Rafael says the 30kg Jam-Air can be installed on any part of the helicopter and that its wide beam more efficient than a directed very narrow laser beam.

Teva predicts $10.75 billion revenue in 2008
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) predicts $10.75 billion and non-GAAP earnings per share of $2.60-2.75 in 2008. The guidance is above the market consensus of $10.41 billion revenue, although in line with earnings per share of $2.67.

Teva CEO Shlomo Yanai predicts that the adjusted earnings per share will exceed $3 in 2009.

Teva added that it now has 160 product applications waiting for US Food and Drug Administration (FDA) approval. The brand products have $100 billion in annual sales. The company added that it believes that it is the first to file on 49 of these products, and that it expects to continue obtaining an average of 12 FDA approvals a year. In addition, the company has 166 applications pending approval.

Reprinted from the Israel High-Tech & Investment Report March 2008

Click HERE to request further information.
Click HERE to go BACK.